Investor Presentaiton

Q3 2023 Opdivo Sales Mix 24% U.S. Sales Mix 11% 20% ll Bristol Myers Squibb Q3 2023 Results Ex-U.S. Sales Mix 24% 21% 29% 7% 21% 25% ■ NSCLC ■ RCC ■ Melanoma ■ Upper GI/Bladder ■ All others Note: percentages are approximate 18% OPDIVO™ (nivolumab) INJECTION FOR INTRAVENOUS USE 10 mg/mL Not for Product Promotional Use 26

View entire presentation